Gagnon R F, Richards G K, Subang R
Department of Medicine, Montreal General Hospital, Quebec, Canada.
ASAIO J. 1992 Jul-Sep;38(3):M596-9. doi: 10.1097/00002480-199207000-00106.
Staphylococcus epidermidis implant infections remain a therapeutic challenge; they frequently result in failure of conservative management and require removal of the implant. This resistance to antibiotic therapy has been ascribed to the presence of a protective bacterial biofilm at the surface of the implant. An animal model of implant associated infection has been developed in which preformed bacterial biofilm catheter segments are implanted intraperitoneally, resulting in a chronic standardized localized infection. The authors have determined the superior rapid action of rifampin (Cieba-Geigy) compared to vancomycin hydrochloride (Eli Lilly) and determined that the combination is superior to either used alone. No rifampin resistant surviving infection was noted, which indicates the significant contribution of mammalian host defenses. This animal model is an excellent vehicle for the study of Staphylococcus epidermidis implant associated infection and the evaluation of the relative efficacy of antibiotic regimens, singly and in combination.
表皮葡萄球菌植入物感染仍然是一个治疗难题；它们常常导致保守治疗失败，需要移除植入物。对抗生素治疗的这种抗性归因于植入物表面存在保护性细菌生物膜。已建立一种植入物相关感染的动物模型，其中将预先形成的细菌生物膜导管段植入腹腔，导致慢性标准化局部感染。作者已确定利福平（西巴-盖吉公司）比盐酸万古霉素（礼来公司）具有更优的快速作用，并确定联合使用优于单独使用任何一种药物。未发现耐利福平的存活感染，这表明哺乳动物宿主防御的重要作用。这种动物模型是研究表皮葡萄球菌植入物相关感染以及评估单一和联合抗生素治疗方案相对疗效的良好载体。
